<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00835406</url>
  </required_header>
  <id_info>
    <org_study_id>00161</org_study_id>
    <nct_id>NCT00835406</nct_id>
  </id_info>
  <brief_title>Alendronate Sodium 70 mg Tablet Versus Fosamax® Under Fasting Conditions.</brief_title>
  <official_title>Randomized, 2-Way Crossover, Bioequivalence Study of Teva Pharmaceuticals USA and Merck Sharp &amp; Dohme (USA) (Fosamax®) Alendronate Sodium Tablets Administered as a 1 x 70 mg in Healthy Adult Males Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the rate and extent of absorption of alendronate
      sodium 70 mg tablets (test) versus Fosamax® 70 mg tablets (reference) administered as a
      single dose of 70 mg under fasting conditions. A review of pharmacokinetic data demonstrates
      Alendronate Sodium Tablets, 70 mg, manufactured and distributed by TEVA Pharmaceuticals USA
      are bioequivalent to Fosamax® Tablets, 70 mg, manufactured by Merck Sharp &amp; Dohme, USA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Criteria for Evaluation: FDA Bioequivalence Criteria

      Statistical Methods: FDA bioequivalence statistical methods
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2000</start_date>
  <completion_date type="Actual">July 2000</completion_date>
  <primary_completion_date type="Actual">July 2000</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence Based on Rmax</measure>
    <time_frame>Urine collected over 36 hour period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence Based on Ae0-36</measure>
    <time_frame>Urine collected over 36 hour period</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Alendronate Sodium First</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>70 mg Alendronate Sodium Tablets test product dosed in first period followed by 70 mg Fosamax® Tablets reference product dosed in second period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fosamax® First</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>70 mg Fosamax® Tablets reference product dosed in first period followed by 70 mg Alendronate Sodium Tablets test product dosed in second period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alendronate Sodium Tablets 70mg</intervention_name>
    <description>1 x 70mg, single dose fasting</description>
    <arm_group_label>Alendronate Sodium First</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosamax® Tablets 70mg</intervention_name>
    <description>1 x 70 mg, single dose fasting</description>
    <arm_group_label>Fosamax® First</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects will be males, non-smokers, between 18 and 45 years of age.

          -  Subjects' weight will be within 15% of their ideal body weight based on the Table of
             &quot;Desirable Weight of Adults&quot;, Metropolitan Life Insurance Company, 1983

          -  Subjects should read, sign, and date an Informed Consent Form prior to any study
             procedures.

          -  Subjects must complete all screening procedures within 28 days prior to the
             administration of study medication.

        Exclusion Criteria:

          -  Clinically significant abnormalities found during medical screening.

          -  Any history or presence of significant neurological, hepatic, renal, endocrine,
             cardiovascular, pulmonary, hematologic, immunologic, psychiatric or metabolic disease.

          -  Any clinically significant history of ongoing gastrointestinal problems or problems
             known to interfere with the absorption, distribution, metabolism or excretion of drugs
             (e.g. chronic diarrhea, inflammatory bowel diseases).

          -  Clinically significant illnesses within 4 weeks of the administration of study
             medication.

          -  Abnormal laboratory tests judged clinically significant.

          -  ECG or vital signs abnormalities (clinically significant).

          -  History of allergic reactions to alendronate or other related drugs (e.g. clodronate,
             etidronate and pamidronate).

          -  History of allergic reactions to heparin.

          -  Any food allergies, intolerances, restrictions, or special diet which in the opinion
             of the medical subinvestigator, contraindicates the subject's participation in this
             study.

          -  Positive urine drug screen at screening or at check-in of period I.

          -  Positive testing for hepatitis B, hepatitis C or HIV at screening.

          -  Use of an investigational drug or participation in an investigational study, within 30
             days prior to administration of the study medication.

          -  Recent donation of plasma (500 mL) within 7 days or recent donation or significant
             loss of whole blood (450 mL) within 56 days prior to administration of the study
             medication.

          -  History of significant alcohol abuse within six months of the screening visit or any
             indication of the regular use of more than two units of alcohol per day (1 Unit =
             150mL of wine or 360 mL of beer or 45 mL of alcohol 40%).

          -  Recent history of drug abuse or use of illegal drugs: use of soft drugs (such as
             marijuana, pot) within 3 months of the screening visit or hard drugs (such as cocaine,
             phencyclidine (PCP), crack) within 1 year of the screening visit.

          -  Subjects who have used tobacco within 90 days of the start of the study.

          -  Subjects who have taken prescription medication 14 days preceding administration of
             study medication or over-the-counter products 7 days preceding administration of study
             medication, except for topical products without systemic absorption.

          -  Subjects who have taken any drugs known to induce or inhibit hepatic drug metabolism
             within 30 days prior to administration of the study medication (examples of inducers:
             barbiturates, carbamazepine, phenytoin, glucocorticoids, rifampin/rifabutin; examples
             of inhibitors: antidepressants, cimetidine, diltiazem, erythromycin, ketoconazole, MAO
             inhibitors, neuroleptics, verapamil, quinidine).

          -  Subjects who have undergone clinically significant surgery 4 weeks prior to the
             administration of the study medication.

          -  Any reason which, in the opinion of the medical subinvestigator, would prevent the
             subject from participating in the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Masson, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anapharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anapharm Inc.</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>GIV2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2009</study_first_submitted>
  <study_first_submitted_qc>January 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2009</study_first_posted>
  <results_first_submitted>April 24, 2009</results_first_submitted>
  <results_first_submitted_qc>April 24, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 11, 2009</results_first_posted>
  <last_update_submitted>June 29, 2009</last_update_submitted>
  <last_update_submitted_qc>June 29, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2009</last_update_posted>
  <keyword>Bioequivalence</keyword>
  <keyword>Healthy Subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alendronate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Alendronate Sodium First</title>
          <description>70 mg Alendronate Sodium Tablets test product dosed in first period followed by 70 mg Fosamax® Tablets reference product dosed in second period</description>
        </group>
        <group group_id="P2">
          <title>Fosamax® First</title>
          <description>70 mg Fosamax® Tablets reference product dosed in first period followed by 70 mg Alendronate Sodium Tablets test product dosed in second period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period: First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period: Washout of 7 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period: Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Alendronate Sodium First</title>
          <description>70 mg Alendronate Sodium Tablets test product dosed in first period followed by 70 mg Fosamax® Tablets reference product dosed in second period</description>
        </group>
        <group group_id="B2">
          <title>Fosamax® First</title>
          <description>70 mg Fosamax® Tablets reference product dosed in first period followed by 70 mg Alendronate Sodium Tablets test product dosed in second period.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="70"/>
            <count group_id="B2" value="70"/>
            <count group_id="B3" value="140"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bioequivalence Based on Rmax</title>
        <description>Rmax = maximum rate of urinary excretion</description>
        <time_frame>Urine collected over 36 hour period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alendronate Sodium</title>
            <description>70 mg Alendronate Sodium Tablets test product dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Fosamax®</title>
            <description>70 mg Fosamax® Tablets reference product dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>Bioequivalence Based on Rmax</title>
          <description>Rmax = maximum rate of urinary excretion</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.96" spread="40.48"/>
                    <measurement group_id="O2" value="73.99" spread="39.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>ANOVA will be performed on ln-transformed Ae0-36 and Rmax at the α level of 0.05.</non_inferiority_desc>
            <param_type>Ratio of the mean</param_type>
            <param_value>97.94</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>90.96</ci_lower_limit>
            <ci_upper_limit>105.45</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bioequivalence Based on Ae0-36</title>
        <description>Ae0-36 = cumulative urine excretion</description>
        <time_frame>Urine collected over 36 hour period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alendronate Sodium</title>
            <description>70 mg Alendronate Sodium Tablets test product dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Fosamax®</title>
            <description>70 mg Fosamax® Tablets reference product dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>Bioequivalence Based on Ae0-36</title>
          <description>Ae0-36 = cumulative urine excretion</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219.28" spread="127.25"/>
                    <measurement group_id="O2" value="213.44" spread="118.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>ANOVA will be performed on ln-transformed Ae0-35 and Rmax at the α level of 0.05.</non_inferiority_desc>
            <param_type>Ratio of the mean</param_type>
            <param_value>100.36</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>92.85</ci_lower_limit>
            <ci_upper_limit>108.48</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Principal Investigator is not permitted to discuss or publish trial results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Manager, Biopharmaceutics</name_or_title>
      <organization>TEVA Pharmaceuticals USA</organization>
      <phone>1-866-384-5525</phone>
      <email>clinicaltrialqueries@tevausa.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

